Jackson Financial, Inc. (JXN)
NYSEFinancialsInsurance - LifeSnapshot 2026-09-04
$140.63+0.92%
Close 2026-09-04 · 1-day change
NYSEFinancialsInsurance - LifeSnapshot 2026-09-04
QuarterlyIQ Insights · JXN
Price, fair value, and the multiples that frame it on the same time axis. Scroll over the price chart to zoom.
Daily closes. Earnings/event dots inline.
A consensus fair price across 13 valuation methods, at three horizons. As of 2026-09-04. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
We take the 12-month fair value above and grade our own number — how the market prices this name versus what we'd justify, and where the two diverge.
At $141 JXN trades at 0.9× p/b, below its 1.3× p/b peer median. Our $254 fair value sits well above the price. We hold it with low confidence: our number sits well above the analyst range. Analysts target $135–$149. Note: our $254 fair value sits above the entire analyst range ($135–$149). Not investment advice.
One valuation read at a 12-month horizon, plus how price compares to peers and the company's own history.
Score 100 = cheapest in the cohort, 0 = richest. Bars are filled left-to-right based on the peer-relative score (or PEG/self-history where shown).
Each method's implied share price per horizon. Provisional rows use a projected (historical-CAGR) growth input rather than analyst or management guidance.
| Method | Horizon | Est. price | Multiple | Per-share input | EPS source | Confidence |
|---|---|---|---|---|---|---|
| analyst target | 12M | $139.50 | — | — | Analyst | high |
| dcf fcfe | 12M | $1146.04 | — | — | Hist. CAGR | high |
| dcf fcff | 12M | $894.04 | — | — | Hist. CAGR | high |
| ddm gordon | 12M | $37.49 | — | — | TTM | high |
| graham number | 12M |
A “consensus-then vs. actual-now” overlay is on the way — what our valuation estimate said on a past date versus where the price actually landed.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
A long-thesis check that carries the widest uncertainty of the three horizons.
Top 25% on quality vs scored peers
$135.00 – $149.00 (median $139.50) · 4 analysts · as of 2026-08-05
No fragility gates fired. Regime (Mania) does not concentrate fragility.
For similar setups historically (n=20,154): about 33% saw a 20%+ drawdown, and roughly 76% of those did not recover within the year. These are historical base rates for the cohort, not a forecast of this stock.
Looks cheaper than most peers in the same business.
Around its own typical valuation.
Trailing four: 2025-Q2, 2025-Q3, 2026-Q1, 2026-Q2
| $290.78 |
| — |
| — |
| TTM |
| high |
| Peer P/B | 12M | $199.75 | 1.3 | 149.01 | TTM | high |
| Peer P/FCF | 12M | $926.14 | 11.1 | 83.72 | TTM | high |
| Peer P/E | 12M | $353.48 | 11.2 | 31.70 | ntm analyst | high |
| Peer P/S | 12M | $265.04 | 2.9 | 92.10 | TTM | high |
| PEG | 12M | $717.48 | 28.4 | 25.22 | TTM | high |
| residual income | 12M | $185.60 | — | — | TTM | high |
| Own P/E history | 12M | $128.40 | 5.1 | 25.22 | TTM | high |
| triangulated | 12M | $323.16 | 12.4 | 26.05 | Triangulated | high |
| Peer P/FCF | 3Y | $956.04 | 11.1 | 86.42 | Hist. CAGR(prov.) | medium |
| Peer P/E | 3Y | $467.48 | 11.2 | 41.92 | Analyst | medium |
| Peer P/S | 3Y | $451.26 | 2.9 | 156.81 | Analyst | medium |
| PEG | 3Y | $1091.19 | 28.4 | 38.36 | Analyst | medium |
| Own P/E history | 3Y | $195.27 | 5.1 | 38.36 | Analyst | medium |
| Peer P/FCF | 5Y | $976.50 | 11.1 | 88.27 | Hist. CAGR(prov.) | high |
| Peer P/E | 5Y | $618.24 | 11.2 | 55.44 | Analyst | high |
| Peer P/S | 5Y | $596.79 | 2.9 | 207.38 | Analyst | high |
| Own P/E history | 5Y | $258.25 | 5.1 | 50.73 | Analyst | high |